Harrow, INC 8-K filings

Harrow Inc. amended its credit agreement to draw $30 million to partially fund a $37 million milestone payment to Novartis related to the commercial availability of Triescence.

Harrow Inc. has released a corporate presentation to be used at investor conferences and meetings.

Harrow Inc. reported record second-quarter revenue of $48.9 million, driven by strong performance across all business segments, particularly IHEEZO and VEVYE.

Harrow, Inc. has appointed Crowe LLP as its new independent auditor, effective June 25, 2024, following the merger of its previous auditor, KMJ Corbin & Company LLP, with Crowe.

Harrow Inc. successfully held its 2024 Annual Meeting of Stockholders, electing all director nominees and ratifying the company's independent auditor.

Harrow, a leading North American eyecare pharmaceutical company, announced a 33% increase in revenues for the first quarter of 2024, reaching $34.6 million, and reaffirmed its full-year revenue guidance of $180 million despite headwinds from the Change Healthcare cyberattack.

Harrow Inc. has received approval from the Centers for Medicare & Medicaid Services (CMS) to increase the Medically Unlikely Edits (MUE) for its IHEEZO product, enabling reimbursement for bilateral procedures.

Harrow, Inc. has received confirmation from the Centers for Medicare & Medicaid Services (CMS) that IHEEZO is separately payable in the physician office setting under Medicare Part B.

Harrow Inc. announced a 47% increase in revenue for 2023, reaching $130.2 million, alongside significant growth in Adjusted EBITDA.

Harrow, Inc. has granted Apotex Inc. exclusive rights to market and distribute five of its ophthalmic pharmaceutical products in Canada.

Harrow Inc. has increased its board size to six members with the appointment of Adrienne L. Graves, Ph.D. and Lauren P. Silvernail, effective immediately.